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Tramadol is an effective pharmacological intervention in human premature ejaculation
(PE). To investigate whether the inhibitory action of tramadol is primarily caused by
its selective serotonin reuptake inhibitory (SSRI) effects we tested the dose–response
effects of tramadol on sexual behavior in serotonin transporter wild type (SERT+/+),
heterozygous (SERT+/−), and knockout (SERT−/−) rats. To investigate whether other
mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT1A receptor
antagonist and naloxone, a µ-opioid receptor antagonist, were tested on sexual
behavior together with tramadol. Tramadol dose-dependently decreases sexual activity
in all genotypes. In all studies, SERT+/− rats did not respond differently from SERT+/+
rats. WAY100,635 did not affect sexual activity in SERT+/+, but dose-dependently
reduced sexual activity in SERT−/− rats. WAY100,635 (0.3 mg/kg) combined with
tramadol (20 mg/kg) significantly reduced sexual activity in SERT+/+ and even stronger
in SERT−/− rats. Naloxone did not affect sexual behavior consistently in SERT+/+
rats, while in SERT−/− rats all doses reduced ejaculation frequency mildly. Combining
naloxone (20 mg/kg) and tramadol (20 mg/kg) decreased ejaculation frequencies in both
genotypes. Interestingly, combining tramadol (20 mg/kg), WAY100,635 (0.3 mg/kg) and
naloxone (20 mg/kg) led to complete elimination of all sexual activity in both SERT+/+
and SERT−/− rats. These findings suggest that the inhibitory effects of tramadol on
male sexual behavior in SERT+/+ rats is mainly, if not exclusively, due to SERT inhibition,
with an important role for 5-HT1A receptors, although influence of other systems (e.g.,
noradrenergic) cannot be excluded. As SSRIs exert their sexual inhibition after chronic
administration, tramadol may be therapeutically attractive as “on demand” therapy
for PE.
Keywords: SSRI, sexual behavior, tramadol, rat, 5-HT1A receptor, µ-opioid receptor, serotonin transporter
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INTRODUCTION
Tramadol is a worldwide used painkiller that produces anti-
nociception by activation of µ-opioid receptors (Hennies et al.,
1988). Recent research has shown that tramadol is effective in
treating premature ejaculation (PE) in humans (Bar-Or et al.,
2012; Eassa and El-Shazly, 2013; Yang et al., 2013). Tramadol
is a racemic mixture of two enantiomers (Frink et al., 1996).
The first enantiomer [(+)-tramadol] and its metabolite [(+)-M1]
are selective agonists of the µ-opioid receptor and have selective
serotonin reuptake inhibitory (SSRI) effects as well; the second
enantiomer [(−)-tramadol] and the (−)-M1 metabolite produce
norepinephrine reuptake inhibition (Matthiesen et al., 1998). Due
to its SSRI properties, tramadol has antidepressant-like effects
(Rojas-Corrales et al., 1998, 2002). SSRIs are mainly used as
antidepressants due to inhibition of the serotonin transporter
(SERT), leading to an increased level of 5-HT in the synaptic
cleft. However, SSRI treatment has been associated with the
appearance of some serious side effects, like a decrease in
the ability to reach ejaculation or orgasm (Balon, 2006); thus
resulting in a significant impact on an individual’s life quality
that in most cases leads to non-compliance to treatment (Higgins
et al., 2010).
Previously, we found (Olivier et al., 2017a) found that
tramadol inhibits sexual behavior in male rats and postulated
this to be mainly due to its SSRI properties, although tramadol’s
µ-opioid receptor agonistic activity might contribute in a minor
way to sexual behavior inhibition. Serotonergic activation of
sexual activity in male rats is primarily based on activation
of 5-HT1A receptors based on the pro-sexual effects observed
after 5-HT1A receptor agonists (Snoeren et al., 2014). Acute co-
administration of a 5-HT1A receptor antagonist and SSRI inhibits
male rat sexual behavior, indicating that the potential sexual side
effects of chronic SSRI-treatment depend on the degree of 5-
HT1A receptor modulation (de Jong et al., 2005a). In the present
research, our rationale is to further investigate the role of 5-
HT1A receptor activity andµ-opioid agonist activity in tramadol’s
sexual behavior inhibition. To this end, we use SERT knockout
rats because they create a possibility to study the influence of
tramadol on the µ-opioid system (and possibly other systems)
without concomitant influence of blockade of the SERT in male
sexual behavior. Although it is known that 5-HT1A receptors
are affected in homozygous SERT knockout (SERT−/−) rats
(Olivier B. et al., 2010; Chan et al., 2011) practically nothing
is known about changes in other systems, including the opioid
system.
In the present studies, based on our previous work (Olivier
et al., 2017a), we first explored several doses of tramadol (5,
10, 20, 40, and 50 mg/kg IP) on sexual behavior of wild type
(SERT+/+), heterozygous (SERT+/−), or SERT−/− male rats,
selected, and trained for average sexual activity (2–3 ejaculations
per 30-min test after a 6-weeks training period). Because we
knew from previous studies (Olivier et al., 2017a) that a higher
tramadol dose (40 mg/kg) in wild type rats could only marginally
be influenced by naloxone, we combined a slightly inhibitory dose
of tramadol (20 mg/kg) in all three genotypes with naloxone,
a µ-opiate receptor antagonist. In another set of studies, we
combined tramadol (20 mg/kg) with a selected, sexual behavior-
inactive dose of the 5-HT1A receptor antagonist WAY100,635
(0.3 mg/kg). The supporting idea of this experiment was our
previous finding that combining sexually inactive doses of a 5-
HT1A receptor antagonist with a sexually inactive dose of an SSRI
after acute administration strongly inhibits sexual behavior (de
Jong et al., 2005a). Lastly, WAY100,635 (0.3 mg/kg) and naloxone
(20 mg/kg) were combined with tramadol (20 mg/kg) to unravel
putative modulatory effects and clarify possible interactions.
MATERIALS AND METHODS
Animals
Wistar rats were bred in our animal facility (University of
Groningen, GELIFES) using SERT+/− males and females,
resulting in male and female SERT+/+, SERT+/−, and SERT−/−
rats. Male SERT+/+, SERT+/−, and SERT−/− rats of at least 12-
weeks old were used for sexual behavioral experiments. Female
SERT+/+ and SERT+/− offspring were used as sexual stimulus
females. Rats were housed under reversed dark-light conditions
(12 h light:12 h dark, lights off from 9:00 AM to 9 PM). Animals
were socially housed (2–5 per cage, maximum 4 for males).
Wooden gnawing blocks and nesting material were provided
for cage enrichment. Rats had ad libitum access to food and
water. All experiments were conducted in accordance with the
governmental guidelines for care and use of laboratory animals
(Centrale Commissie Dierproeven). The protocol was approved
by the Central Commissie Dierproeven. All efforts were made to
minimize the number of animals and possible suffering.
Female Rats
The females had double tubal ligation to prevent pregnancies.
To perform the surgery, females were anesthetized (Isoflurane)
and given pain relief (Fynadine, 0.1 mg/100 g) before the surgery,
and 24 and 48 h after surgery. Females were at least 12-weeks
old when surgery was performed, and 2 weeks of recovery were
given before they were made intentionally receptive with estradiol
(50 µg in 0.1 ml oil, S.C., 36–48 h before the test) for the sexual
behavior training tests and experiments. Females were used once
in 2 weeks and not more than two times per experimental day.
Drug Treatment and Behavioral
Experiments
A crossover-randomized design was planned in order to
prevent that animals receive the same drug doses or vehicle
during all the experiments, which were run over a couple
of months. As described previously in Olivier et al. (2017a),
when pharmacological tests were performed, male rats were
given a 30-min habituation time in the test boxes right after
drug administration via IP injection, before the female rat was
introduced. Multiple injections were given 10 min after each
other. All behavior during the 30-min test was video-recorded
after introduction of the female and were also live scored and
the following parameters of the first ejaculation series were
deduced (Chan et al., 2010): number of ejaculations (E), number
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of mounts (M), number of intromissions (I), latency (s) to first
mount (ML), latency (s) to first intromission (IL) and latency
(s) to the first ejaculation (EL). After ejaculation, the post-
ejaculatory interval (PEI) was calculated, using the time from
the first ejaculation and the time of the first mount/intromission
(whatever occurred first) of the second ejaculation series.
Intromission ratio (IR) was calculated as: IR = (#I/(#I + #M)) ∗
100%. EL was calculated using the time from the first ejaculation
series minus the intromission latency of the first ejaculation
series. The percentages of animals performing sexual behavior
during the experimental period can be found in Supplementary
Figure 2.
Because it is important to have comparable
pharmacodynamics and kinetics in pharmacological studies,
a test of fixed duration has been chosen; 30 min (1800 s).
Parameters from only the first ejaculation series, which includes
the first PEI, were used to run the statistical analysis. The
rationale behind this is that some treatments can decrease sexual
behavior to zero (e.g., zero ejaculations) and some animals
cannot be used to perform statistics. For those cases, we used
artificial values of 1800 s (i.e., the maximum test duration) for
some latencies (ejaculation, mount, and intromission latency),
although this is undoubtedly a matter of discussion as we have
mentioned before (Chan et al., 2010; Olivier et al., 2017a). In the
cases in which drugs inhibited ejaculatory behavior, few or no
animal achieve a second ejaculation and statistical analyses of
the second ejaculatory series was not possible. If a drug blocked
ejaculation and sexual performance, data values attributed to EL,
ML, IL were 1800 s and the frequencies values (MF and IF) for all
animals for statistical purposes. All tables and figures show the
results for the first Ejaculation Series.
Drugs
Tramadol hydrochloride (Pharmacy, UMC Groningen,
Netherlands) was prepared from tablets obtained from
a local pharmacy, grinded and suspended in 0.9% NaCl
(saline). Naloxone hydrochloride (Abcam; Cambridge,
United Kingdom) and WAY100,635 maleate (Tocris Bioscience;
Bristol, United Kingdom) were dissolved in saline and each
solution was freshly prepared on each testing day. All drugs were
administered via intraperitoneal (IP) injection.
Training
After 6-weekly training tests (30 min/test), male rats were
considered sexually trained and classified based on ejaculation
frequencies per test in: average (2–3 ejaculations/test), fast (>3
ejaculations/test), and slow (0–1 ejaculations/test) groups (Pattij
et al., 2005; Olivier et al., 2006; Chan et al., 2008). Accordingly,
95 males were sexually trained and a total of 36 male rats
with an average number of ejaculations were selected and
used during all the experiments, which lasted 25 weeks. In all
individual experiments 12 rats per genotype [SERT+/+ (N = 32),
SERT+/− (N = 32), and SERT−/− (N = 31)] were used and
animals were used only once a week to guarantee sufficient
drug washout time. Rats had a habituation period of 10 min
in the testing box right before the training session. At the end
of the habituation period a receptive female was introduced in
the box and sexual behavior was assessed for 30 min. Females
that were not receptive were switched for a different female that
showed receptivity. The training and testing occurred in wooden
rectangular (57 cm × 82 cm × 39 cm; glass wall) testing boxes
filled with regular bedding material. To stimulate sexual behavior,
bedding material was not changed during the training and testing
to preserve pheromones of previous rounds and to create a more
competitive sexual environment. The sexual parameters scored
were: total number of ejaculations of all the tests; the total number
of mounts and intromissions per ejaculatory series and their
respective latencies were scored for weeks 2, 3, and 6. Only males
showing stable ejaculation levels (2–3 ejaculations on the last
training tests) were used for the pharmacological experiments
(N = 12 per genotype, 36 in total). Although male SERT−/− rats
generally display a lower sexual behavior level than SERT+/+
rats (Olivier B. et al., 2010; Chan et al., 2011), we selected
the highest performing SERT−/− animals, determined by the
number of ejaculations/test, for these experiments to avoid base-
line differences that complicate drug studies. All training sessions
and experiments were performed under red light conditions
between 10:00 AM and 17:00 PM.
Pharmacological Experiments
Experimental Design
We selected 36 male rats from a pool of 95 males that were
trained weekly for 6 weeks on their basal sexual behavior. These
36 rats (12 of each genotype) did not differ in their sexual level of
performance. Four experiments were performed on these 36 rats,
performing one test per week on each rat. Doses of drugs and
vehicle tested were distributed via a crossover design. Between
experiments at least 1 week of rest (non-testing) was given.
Experiment 1
Tramadol dose–response. Thirty-six average ejaculating male rats
were selected (N = 12 per genotype). The three groups went on
a crossover design and received vehicle (saline), 5, 10, 20, 40,
and 50-mg/kg tramadol, IP (tramadol hydrochloride). Because
it was physically not possible to test 36 animals in one test-day,
we performed testing per week on two consecutive testing days
(always the same 2 days) over 6 weeks and randomized animals
and treatment over these 2 days and over the 6 weeks.
Experiment 2
WAY100,635 dose–response. The same 36 animals were used on
a crossover design to receive vehicle (saline), 0.1, 0.3, and 1 mg/kg
WAY100,635, IP. Testing was performed over 4 weeks and two
consecutive days per week.
Experiment 3
Naloxone dose–response. The same 36 animals were used on a
crossover design received vehicle (saline), 5, 10, and 20 mg/kg
naloxone, IP. Testing was performed over 4 weeks and two
consecutive days per week.
Experiment 4
Tramadol + WAY100,635 + Naloxone. All 36 rats were
treated using a crossover design with
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vehicle + vehicle, vehicle + tramadol (20 mg/kg),
tramadol (20 mg/kg) + WAY100,635 (0.3 mg/kg),
tramadol (20 mg/kg) + naloxone (20 mg/kg) or tramadol
(20 mg/kg) +WAY100,635 (0.3 mg/kg) + naloxone (20 mg/kg)
using IP dosing. This experiment was performed over 6 weeks
and two consecutive days per week.
Statistical Analyses
For the tramadol, WAY100,635 and naloxone dose–response
experiments data were normally distributed and analyzed
with parametric tests, performing one-way ANOVA with
repeated measures and Bonferroni post hoc statistical analysis
(within group) and two-way ANOVA and Dunn post hoc
test (between groups) to analyze these data. For the last
experiment (Tramadol + WAY100635 + Naloxone) data were
not normally distributed and non-parametric statistics were
performed; Friedman repeated measures test with a rank
sum tests (Tukey-HSD) post hoc and a Friedman two-way
ANOVA with multiple comparisons. All data were analyzed
using GraphPad Prism software 6.0 (Graph Pad Software, Inc.,
La Jolla, CA, United States). Level of significance was set at
p < 0.05. Parametric data are expressed as mean ± SEM and




The sexual performance of the animals during the duration
of the study stabilized throughout the training session period.
From the 95 male rats sexually trained, only 36 animals that
showed sexual performance and ejaculations were selected to
do the pharmacological studies (SERT+/+ and SERT+/−: 2–3
ejaculations; SERT−/−: 1–2 ejaculations). During this period, the
number of ejaculations was registered, and animals showed stable
ejaculatory behavior (Figure 1). The ejaculation frequencies of
SERT+/− animals were never significantly different from the
SERT+/+ rats; SERT−/− rats did not significantly differ in
ejaculation frequencies compared to wild type rats over the whole
duration of the experiments. Because SERT+/− animals did
not show any significant differences from SERT+/+ rats at any
time point in any drug experiment, all results of the SERT+/−
animals have not been used, but all data can be found in the
Supplementary Figures 1–4 and Supplementary Tables 11–14.
Because we tested the experimental animals over an extensive
period of time (more than half a year) a risk of changes in the
sexual performance level over time might be present. Moreover,
animals received sequentially a considerable number and doses
of different drugs. Although at least always 1-week wash-out
was applied, the possibility exists that “carry-over” effects might
occur. We did not find any evidence for either changes in the
basal level of sexual behavior over time, or any “carry-over” drug
effects. Figure 1 illustrates that the “vehicle” (placebo) values (e.g.,
of ejaculation frequency) of the three genotype groups are very
constant over time (at least 26 weeks; Supplementary Table 1).
FIGURE 1 | Distribution of ejaculation frequencies of male Wistar rats that
were sexually trained over 6 weeks (total n = 95; SERT+/+ n = 32, SERT+/−
n = 32, and SERT−/− n = 31) and pharmacologically tested from week 7 to
25 (total n = 36; SERT+/+ n = 12, SERT+/− n = 12, and SERT−/− n = 12).
These findings are in line with our earlier experiments using
tramadol (Olivier et al., 2017a) and others (Olivier et al., 2017b).
Dose–Response of Tramadol
In the dose–response experiment (Experiment 1; Figure 2 and
Supplementary Tables 3, 4) the lowest doses of tramadol (5 and
10 mg/kg) had no significant effects on sexual behavior; the
intermediate and high doses (20, 40, and 50 mg/kg) induced
significant effects on behavioral parameters of sexual behavior
(Figure 2) in SERT+/+ animals, whereas only doses of 40 and
50 mg/kg induced significant effects in SERT−/− rats. At these
high doses, numbers of E, M, and I were significantly decreased
and latencies of E, M, and I were significantly increased compared
to the placebo (saline) group. The 50-mg/kg dose provoked
a dramatic reduction of sexual activity in both SERT+/+ and
SERT−/− animals. The 20 mg/kg dose significantly increased
mount and intromission latencies and significantly decreased the
intromission frequency in SERT+/+ animals, and the number of
intromissions were significantly different between genotypes.
Dose–Response of WAY100,635
WAY100,635 (0.1, 0.3, and 1 mg/kg) had no significant effects on
sexual parameters in SERT+/+ animals; however, in SERT−/−
rats all doses significantly reduced EF and increased EL (Figure 3
and Supplementary Tables 5, 6) when compared to saline. M (at
1 mg/kg) and I (at 0.3 and 1 mg/kg) frequencies, and IR (at 0.1,
0.3, and 1 mg/kg) were significantly decreased, whereas M and
I latencies (at 0.3 and 1.0 mg/kg) were significantly increased in
SERT−/− rats compared to SERT+/+ rats.
Dose–Response of Naloxone
Naloxone had very limited effects in the SERT+/+ animals; only
the 5-mg/kg dose decreased the ejaculation frequency (Figure 4
and Supplementary Tables 7, 8), but not in SERT+/− rats.
Naloxone (5, 10, and 20 mg/kg) had significant effects on the
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FIGURE 2 | Sexual behavior of male rats (N = 12/group) treated with 0, 10, 20, 40, or 50 mg/kg tramadol. Data are given as mean ± SEM. The number and latency
of ejaculations per 30 min (A,D), number and latency of Mounts (B,E), number and latency of Intromissions (C,F) of the first Ejaculation Series are given. Detailed
statistical analyses (ANOVA repeated measures) are shown in Supplementary Tables 1, 2. a: Significant difference (p < 0.05) compared to saline group. +: Significant
difference between SERT+/+ and SERT−/− (p < 0.05).
ejaculation frequency of SERT−/− rats, slightly decreasing (but
not in a dose-dependent way) the number of ejaculations. The
rest of the parameters (M and I frequencies and latencies) was not
significantly affected in either SERT+/+ or SERT−/− animals.
The efficiency to reach ejaculation (IR) was increased after 10 and
20 mg/kg naloxone administration in SERT+/+ animals.
WAY100,635, Naloxone and Tramadol
Interactions
Tramadol (20 mg/kg) did not induce significant differences
compared to placebo (S + S) in either SERT+/+ or SERT−/−
animals (Figure 5 and Supplementary Tables 9, 10). Combining
tramadol (20 mg/kg) with 0.3 mg/kg WAY100,635 compared
to vehicle (S + S), induced significant decreases in EF
and MF, and an increase in ML in SERT+/+ rats, whereas
in SERT−/− rats all parameters were significantly affected;
decreases in EF, MF, IF, and IR, increases in EL, ML, and
IL. However, no significant differences were present in any
parameter between SERT+/+ and SERT−/− rats. Combining
tramadol (20 mg/kg) with 20 mg/kg naloxone, compared to
vehicle, induced significant decreases in EF, MF, and IF and
significant increases in ML and IL in SERT+/+ rats, whereas
in SERT−/− rats EF and IF were significantly decreased. Effects
on IF, ML, and IL were significantly stronger in SERT+/+
animals compared to SERT−/− animals. The combination of
0.3 mg/kg WAY100,635 + 20 mg/kg naloxone + 20 mg/kg
tramadol completely abolished sexual behavior in SERT+/+ and
SERT−/− rats (Figure 5).
DISCUSSION
When administered acutely (IP), low doses of tramadol (5
and 10 mg/kg) have no significant effects on sexual behavior
of SERT+/+, SERT+/−, and SERT−/− male rats, selected for
normal levels of ejaculation (around 2–3 ejaculations/test).
The 20-mg/kg tramadol dose was clearly at the boundary of
pharmacological relevance. Some minor, but inconsistent effects
were seen. At doses of 40 and 50 mg/kg tramadol significantly
inhibited sexual performance of all SERT genotypes, with the
strongest effect at the 50-mg/kg dose that nearly reduced it to
zero. These findings essentially replicated our earlier findings on
the effects of tramadol on male sexual behavior in rats (Olivier
et al., 2017a). We tried to gain further understanding whether
the effects of tramadol on sexual behavior are consequence of
the 5-HT reuptake inhibiting effects of tramadol and/or action
on the µ opiate receptor. In previous investigations of our
research group, performed only on wild type Wistar rats (Olivier
et al., 2017a), it was hypothesized that the inhibitory effects
on sexual behavior after acutely administered tramadol, were
mainly due to its SSRI properties but could not exclude a role
for the µ-opioid receptor (Olivier et al., 2017a). We decided to
test tramadol also in SERT-knockout rats (both heterozygous
and homozygous knockout animals) in order to exclude the
SSRI component in the mechanism of action of tramadol in
its sexual inhibiting effects. Because the effects of all drugs and
doses used (tramadol, WAY100,635, naloxone and combinations)
in heterozygous SERT+/− rats did not essentially deviate from
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FIGURE 3 | Sexual behavior of male rats (N = 12/group) treated with saline, WAY100,635 0.1 mg/kg, WAY100,635 0.3 mg/kg, or WAY100,635 1 mg/kg. Data are
given as mean ± SEM. The number and latency of ejaculations per 30 min (A,D), number and latency of Mounts (B,E), number and latency of Intromissions (C,F),
and Copulatory Efficiency (G). Detailed statistical analyses (ANOVA repeated measures) are shown in Supplementary Tables 3, 4. a: Significant difference (p < 0.05)
compared to saline group. +: Significant difference between SERT+/+ and SERT−/− (p < 0.05).
those in SERT+/+, we did not use the SERT+/− data, but all
information is given in Supplementary Information.
Surprisingly, tramadol exerted comparable inhibitory actions
on sexual behavior in SERT+/+ and SERT−/− rats (Figure 2).
We had expected that tramadol would exert less inhibitory effects
on sexual behavior in the SERT−/− rats because of the absence
of any SERT molecule in this genotype (Homberg et al., 2007).
Apparently, the other main mechanism of action present in
tramadol, agonism for the µ-opiate receptor, might have caused
the inhibitory sexual action in the knockout rats. If so, it was
expected that naloxone, a µ-opiate receptor antagonist, would
antagonize the tramadol-induced decrease in sexual behavior in
SERT−/− rats. However, the dose of 20 mg/kg naloxone, that
had limited (only inhibition of ejaculation frequency) effects
in SERT−/− rats on its own (Experiment 3; Figure 4), was
neither able to antagonize the effect of tramadol on ejaculation
frequency nor had any further inhibiting effects on other sexual
parameters. Actually, this dose of naloxone combined with
tramadol (20 mg/kg), did not change the behavior consistently
compared to naloxone alone. This suggests that the sensitivity
of the µ-opioid system in the brain of SERT−/− rats had not
been changed due to lifelong absence of the SERT. No data has
been published in SERT−/− rats on sensitivity of the opioid
system, but in SERT−/− mice the limited evidence suggests
that the pharmacological sensitivity for the analgesic effects of
morphine is unaltered (Hall et al., 2011). Remarkably, naloxone
(Figure 3) had, at all doses tested in the dose–response study
(5–20 mg/kg), but also in the single dose study (Figure 5), a
very consistent, but not dose-dependent effect on ejaculation
frequency in the SERT−/− rats but not so in the SERT+/+. In
our previous tramadol studies in Wild type Wistar rats (Olivier
et al., 2017a), 5 and 10 mg/kg naloxone had no effect on male rat
sexual behavior, whereas 20-mg/kg naloxone was more inhibitory
on sexual behavior than in the present experiments. Although
in the previous study (Olivier et al., 2017a) some evidence was
present that a relatively low dose of naloxone (10 mg/kg) very
marginally antagonized some parameters of sexual behavior (ML
and EL) after a high tramadol dose (50-mg/kg) that reduced all
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FIGURE 4 | Sexual behavior of male rats (N = 12/group) treated with saline, Naloxone 5 mg/kg, Naloxone 10 mg/kg, or Naloxone 20 mg/kg. Data are given as
mean ± SEM. The number and latency of ejaculations per 30 min (A,D), number and latency of Mounts (B,E), number and latency of Intromissions (C,F), and
Copulatory Efficiency (G). Detailed statistical analyses (ANOVA repeated measures) are shown in Supplementary Tables 5, 6. a: Significant difference (p < 0.05)
compared to saline group. +: Significant difference between SERT+/+ and SERT−/− (p < 0.05).
sexual behavioral parameters, we did not repeat this experiment
in the present studies because the emerging data did not point to
a strong influence of the opioid system in tramadol’s effects on
sexual behavior. Other ligands with µ-opiate receptor agonistic
activity like morphine that inhibited male sexual behavior in
rats (McIntosh et al., 1980; Ågmo and Paredes, 1988) could
be, dose-dependently and completely, antagonized by naloxone.
Moreover, like in our hands, the intrinsic activity of naloxone
on male rat sexual behavior is not clear-cut (Gessa et al., 1979;
Myers and Baum, 1979; McIntosh et al., 1980), reporting both
stimulatory and inhibitory effects. Apparently, other factors
contributing to the inhibitory effects of tramadol on male sexual
activities are probably more important than the contribution of
the opioid system.
As suggested in our previous study (Olivier et al., 2017a),
we think that the inhibitory effects of tramadol on male sexual
behavior in the SERT+/+ animals are mainly (if not exclusively)
due to blockade of the SERT. When in SERT+/+ rats an acute
dose (20 mg/kg) of tramadol that has no consistent effects on
sexual behavior, is combined with 0.3 mg/kg WAY100,635, a 5-
HT1A receptor antagonist that also does not affect sexual behavior
on its own (Figure 5), sexual behavior is inhibited, confirming
our earlier data (Olivier et al., 2017a). It is postulated that the
inhibitory action of SSRIs on male sexual behavior is mediated via
5-HT1A receptors (de Jong et al., 2005a; Olivier B. et al., 2010). It
is found (Bloms-Funke et al., 2011) that the SSRI component in
tramadol leads to enhanced levels of extracellular concentrations
of 5-HT in the brain. Actually, the (+)-enantiomer and its (+)-
M1 metabolite of tramadol have serotonin-reuptake inhibiting
effects, whereas the (−)-enantiomer and its (−)-M2 metabolite
have noradrenalin reuptake inhibiting effects (Matthiesen et al.,
1998). The latter enantiomer causes the enhanced extracellular
noradrenaline levels due to blockade of the noradrenalin
transporters (NET) (Bloms-Funke et al., 2011). SSRIs hardly
enhance 5-HT after acute administration, e.g., in the frontal
cortex (Beyer et al., 2002; Beyer and Cremers, 2008). This
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FIGURE 5 | Sexual behavior of male rats (N = 12/group) treated with saline + saline (S + S), tramadol (20 mg/kg) + saline (T + S), tramadol
(20 mg/kg) + WAY100,635 (0.3 mg/kg) (T + W), tramadol (20 mg/kg) + Naloxone (20 mg/kg; T + N), and tramadol (20 mg/kg) + WAY100,635
(0.3 mg/kg) + Naloxone (20 mg/kg; T + W + N). The number and latency of ejaculations per 30 min (A,D), number and latency of Mounts (B,E), number and latency
of Intromissions (C,F), and Intromission Rate (G). Detailed statistical analyses (Friedman test) are shown in upplementary Tables 7, 8. a: Significant difference
(p < 0.05) compared to saline + saline group. +: Significant difference between SERT+/+ and SERT−/− groups (p < 0.05).
phenomenon possibly causes the lack of sexual inhibitory effects
of SSRIs after acute administration (Olivier et al., 2017b).
Pharmacological experiments with the (+)- and (−)-enantiomers
of tramadol have not been performed but might be helpful
in further determining the role of the noradrenergic vs. the
serotonergic uptake properties of tramadol on sexual behavior.
Adding a 5-HT1A receptor antagonist to an SSRI leads to
acute enhanced 5-HT levels in the brain (Beyer et al., 2002).
These enhanced 5-HT levels very likely lead to acute and
dose-dependent inhibition of male sexual behavior by SSRIs
(de Jong et al., 2005a,b,c; Olivier B. et al., 2010; Olivier et al.,
2017a). Our findings with tramadol are in line with the SSRI
data. Lower doses of tramadol have relatively small enhancing
effects on extracellular 5-HT levels in the ventral hippocampus,
but higher doses have considerable enhancing effects (Bloms-
Funke et al., 2011), associated with sexual inhibiting effects at
high tramadol doses in our present study. The 20 mg/kg dose
of tramadol has no or only very limited sexual inhibitory effects
but combined with 0.3 mg/kg WAY100,635, strong inhibitory
effects are found. These data strongly suggest, in analogy to SSRIs,
that chronic tramadol treatment in wild type rats will lead to
inhibition of male rat sexual behavior.
As shown before (Chan et al., 2011) and replicated in
our studies here, SERT−/− rats, but not SERT+/− rats, have
a basal lower level of sexual behavior. Because we wanted
to study drugs on animals with comparable basal levels of
sexual performance, we selected the better performing SERT−/−
males (N = 12) from the training pool (N = 31) after 6
weekly training sessions of 30 min (Figure 1). In all the
pharmacology experiments (Figures 2–5) the vehicle data of
these SERT−/− animals never deviated significantly from the
SERT+/+ males, indicating the stability of the two genotypes
over time. Remarkably, the SERT+/− rats never deviated in any
aspect or under any pharmacological treatment from SERT+/+
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rats, confirming earlier data (Chan et al., 2011). The basal
level of sexual behavior in SERT−/− rats is comparable to that
of chronically SSRI-treated rats (de Jong et al., 2005a,b, 2006;
Olivier et al., 2017b). Acute administration of SSRIs at doses that
reach>80% SERT occupancy, does not reliably induce inhibition
of sexual behavior. Likely, adaptations (down regulation) in the
SERTs occur after chronic SSRI treatment that underlies the
changed sexual performance (Oosting et al., 2016).
SERT−/− rats display severe disturbances in serotonergic
signaling and homeostasis (Homberg et al., 2007), including
strongly reduced 5-HT tissue levels and depolarization-induced
5-HT release. Basal extracellular 5-HT levels were nine-fold
increased, whereas no major adaptations in other monoaminergic
systems (noradrenalin and dopaminergic systems) were found.
Constitutive absence of the SERT leads to several adaptations
in the serotonergic system, where in particular adaptations of
5-HT1A receptors are present (Homberg et al., 2008; Olivier
et al., 2008). Earlier studies in SERT−/− rats with regard to male
sexual behavior (Chan et al., 2011) suggested that lifelong absence
of the SERT might have differential effects on two different
pools of 5-HT1A receptors. One pool of 5-HT1A receptors with
unchanged sensitivity seems to mediate the pro-sexual effects
of 5-HT1A receptor agonists like 8-OH-DPAT (Chan et al.,
2011), whereas the other pool, mediating the inhibitory effects
of blocked 5-HT1A receptors, appears sensitized in the SERT−/−
rats (Chan et al., 2011). This complex of two differentially
regulated 5-HT1A receptor pools in SERT−/− rats has also
been found in autonomic regulation of body temperature and
stress responses (Olivier et al., 2008). This pool of sensitized 5-
HT1A receptors leads to an enhanced response to WAY100,635,
which was confirmed in the present study. WAY100,635 had no
behavioral effects in SERT+/+ rats, but strongly (and somewhat
dose-dependently) inhibited male sexual behavior at all doses
in SERT−/− rats. Combination of tramadol and WAY100,635
at doses that by themselves had no sexual behavior effects in
SERT+/+ rats, led to inhibition of sexual behavior in both
SERT+/+ and SERT−/− animals, although stronger (but not
significantly) in the SERT−/− rats (Figure 5). Apparently, in
SERT+/+ rats, adding an SSRI effect (in tramadol) to blockade
of 5-HT1A receptors on itself leads to sexual inhibition, whereas
the tramadol +WAY100,635 combination in SERT−/− animals
does not inhibit more than WAY100,635 alone.
Combining tramadol (20 mg/kg) + naloxone
(20 mg/kg)+WAY100,635 (0.3 mg/kg) led to severe inhibition of
sexual behavior in both SERT+/+ and SERT−/− rats (Figure 5).
The tramadol/WAY100,635 combination in SERT+/+ rats
has already considerable inhibitory effects, adding this to a
naloxone dose (20 mg/kg) that is ineffective by itself, knocks
the sexual behavior almost completely out. This holds also
for the SERT−/− animals. It is unclear how to explain this
wiping out of all active behaviors, but behaviorally non-specific
factors (sedation, motor disturbances, or otherwise) might
be involved. Whether pharmacokinetic interactions might
be involved is unclear, but tramadol (racemic) is extensively
metabolized within the experimental period (30–60 min after
injection) and rapidly, active metabolites (+ and – enantiomers)
are formed (Sheikholeslami et al., 2016). In our experiments
the 20 mg/kg dose played a prominent role in our behavioral
studies, and this dose (Sheikholeslami et al., 2016) led to
plasma and cerebrospinal fluid (CSF) levels of (+ and –
tramadol) and M1 and M2 metabolites that rapidly reached
peak plasma and CSF levels; plasma levels of all components
were at least at a constant high level during the first 60 min,
the time that we conducted our experiments. It is, however,
possible that a combination of tramadol with either naloxone
and/or WAY100,635 might have led to pharmacokinetic
interactions, e.g., via modulation of the CYP450-mediated
phase I metabolic reactions of racemic tramadol responsible
for the emergence of the behaviorally active metabolites M1
and M2. In humans, phase I metabolism runs primarily via
CYP2D6 and CYP3A4 (Miotto et al., 2017). Although not
extensively investigated, there seems to be a large similarity
between human and rat metabolism of tramadol (Sheikholeslami
et al., 2016). Unfortunately, nothing is known about the
exact pharmacokinetics and metabolism of WAY100,635
whereas data on naloxone are also scarce, particularly in
rats. Unfortunately, this means that we cannot conclude that
the combination treatments of tramadol with WAY100,635
and naloxone are influenced via metabolizing effects due to
facilitation or inhibition of certain CYP450 systems in the liver
or brain.
Finally, a putative role for the noradrenalin-reuptake effects
of tramadol should be considered. It might be possible that
NET have (partly) taken over the role of the SERT in order
to compensate for the loss of the SERT in the SERT−/− rat.
Although there is some minor evidence for promiscuity of the
NET for 5-HT (Homberg et al., 2007), there is considerable
evidence (Olivier J.D.A. et al., 2010) that SERT−/− rats have
adapted their catecholaminergic systems to compensate for a
life-long disturbed 5-HT neurotransmission and that drugs
that influence such systems might have differential effects
in SERT+/+ and SERT−/− rats. Preliminary evidence with
atomoxetine, a NET-inhibitor, did not point to differences in
sexual behavior in SERT+/+ and SERT−/− rats (data not shown),
suggesting that the effects of tramadol in both genotypes are
largely, if not exclusively due to changes in the serotonergic
system.
CONCLUSION
All the data gathered thus far suggest that the inhibitory action
of tramadol on male sexual behavior is mainly, if not exclusively
due to the blockade of the SERT, a mechanism that also in SSRIs
is responsible for its inhibitory action on the ejaculation latency
in males with premature ejaculation.
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